Posted on 10/25/19
Biogen Aducanumab Reversal Is Stunning, But Don't Expect A Repeat For Other Alzheimer's Drugs
SummaryBiogen’s Alzheimer’s drug aducanumab was brought back from the dead after new data collected showed efficacy in slowing cognitive impairment.Investors may start chasing other failed beta . . .
Posted on 7/29/19
Johnson & Johnson et al: Rumored $100B Opioid Settlement Could Upend Pain Management Companies
Summary In my previous article on this top, I asserted that a Washington Post exposé on the opioid epidemic was largely irrelevant to the stocks involved. . . .
Posted on 7/29/19
Johnson & Johnson et al: Rumored $100B Opioid Settlement Could Upend Pain Management Companies
SummaryIn my previous article on this top, I asserted that a Washington Post exposé on the opioid epidemic was largely irrelevant to the stocks involved.That is . . .
Posted on 5/22/19
Pfizer: Added Value For A Defensive Pharma Portfolio
Summary Of the 6 largest pharmaceutical companies by market cap, Pfizer is the most balanced and with the shallowest patent cliff. Its best selling drugs are . . .
Posted on 5/22/19
Pfizer: Added Value For A Defensive Pharma Portfolio
SummaryOf the 6 largest pharmaceutical companies by market cap, Pfizer is the most balanced and with the shallowest patent cliff.Its best selling drugs are immune to . . .
Posted on 4/10/19
Biogen Alzheimer's Failure Is Not Surprising, More Will Follow
SummaryBiogen’s Alzheimer’s aducanumab failure heaps on more evidence that beta amyloid plaque is an effect of Alzheimer’s rather than the cause.Other companies pursuing the beta amyloid . . .
Posted on 7/16/18
Pfizer Is Not An All-Powerful Price-Hiker
For a supposedly greedy, all-powerful, price-hiking Big Pharma megacap, Pfizer's (PFE) stock sure isn't doing too well over the long term. There seems to be this . . .
Posted on 4/17/18
Pfizer's DMD Drug Could Spell Long-Term Trouble For Sarepta
Pfizer Inc. (NYSE:PFE) has dosed its first patient in a Phase 1 trial for its Duchenne muscular dystrophy drug PF-06939926. The asset was acquired during Pfizer’s . . .
Boston
